The Neurology of AIDS by Howard E. GendelmanThe Neurology of AIDS by Howard E. Gendelman

The Neurology of AIDS

EditorHoward E. Gendelman, Igor Grant, Ian Paul Everall

Hardcover | November 24, 2011

Pricing and Purchase Info

$280.74 online 
$295.00 list price
Earn 1,404 plum® points

Prices and offers may vary in store


Ships within 1-3 weeks

Ships free on orders over $25

Not available in stores


Neurological complications of progressive HIV-1 infection remain a common cause of morbidity even during widespread use of antiretroviral therapy (ART). Long-term resistance to ART, drug compliance, untoward drug side effects, a myriad of opportunistic infection, depression and otherpsychiatric disease manifestations, concomitant drug abuse, neuropathies, and an inability to clear viral reservoirs, explain, in large measure, disease progression and immune deterioration. These are associated with a number of psychiatric, muscle, nerve, infectious, as well as cognitive,behavioral, and motor disturbances seen in infected people. Fully updated from the previous two editions and replete with color images, The Neurology of AIDS, Third Edition covers each of these neurological complications and more with a focus on molecular and viral disease processes, cellular factors influencing viral replication therapeutic challenges, andthe changing epidemiological patterns of disease. From basic science to clinical care, to epidemiological disease patters, The Neurology of AIDS is the only complete textbook available on AIDS neurology and the only one comprehensive enough to stand alone in each segment of study in brain disordersaffected by the human immunodeficiency virus. It is an indispensable resource for students, resident physicians, practicing physicians, and for researchers and experts in the HIV/AIDS field.
Howard E. Gendelman, MD, is Professor and Chair in the Department of Pharmacology and Experimental Neuroscience at the University of Nebraska Medical Center. Omaha, NE. Igor Grant, MD, is Distinguished Professor of Psychiatry and Director of the HIV Neurobehavioral Research Program at the University of California-San Diego, La Jolla, C...
Title:The Neurology of AIDSFormat:HardcoverDimensions:1160 pages, 11 × 8.5 × 0.98 inPublished:November 24, 2011Publisher:Oxford University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:019539934X

ISBN - 13:9780195399349


Table of Contents

1. HIV-1 Biology and ImmunologyMichael Bukrinsky and Sergey Iordanskiy: 1.1. HIV-1 BiologySabita Roy, Subhash Dhawan, Shilpa Buch, and Krishnakumar Devadas: 1.2. HIV-1 ImmunologyRichard J. Miller: 1.3 ChemokinesChristopher Power, Jennifer A. McCombe, Shaona Acharjee, and M. John Gill: 1.4 Viral and host genetic factorsSunil K. Ahuja, Srinivas Mummidi, Jason F. Okulicz, Edwina J. Wright, and Weijing He: 1.5 Genetic Susceptibilities in neuroAIDS2. Innate and Cellular Immunity and NeurogenesisKenneth C. Williams, William Hickey, Tricia H. Burdo, and Caroline Soulas: 2.1. Mononuclear phagocytesSunhee C. Lee: 2.2. MicrogliaEtty N. Benveniste, Lisa N. Akhtar, and Brandi J. Baker: 2.3. AstrocytesHoward E. Gendelman, Jessica A.L. Hutter, Larisa Poluektova, and Subhash Dhawan: 2.4. Adaptive ImmunityR. Lee Mosley, Max V. Kuenstling, and Eric J. Benner: 2.5. VaccinesJialin C. Zheng, James B Reinecke, Hui Peng, Yunlong Huang, and Qiang Chen: 2.6. Neurogenesis3. Blood brain barrier and HIV CNS EntryWilliam A. Banks: 3.1. Blood brain barrier: Structure and functionMichal Toborek, Ibolya E. Andras, Cetewayo S. Rashid, Yu Zhong, and Shinsuke Nakagawa: 3.2. Endothelial cell biology and HIV-1 infectionYuri Persidsky and Servio H. Ramirez: 3.3. Blood-brain barrier during neuroinflammationEliseo A. Eugenin and J.W. Berman: 3.4. Mechanisms of viral and cell entry into the CNSGeorgette D. Kanmogne: 3.5. Monocyte-macrophages and viral CNS entry4. Cellular and Viral Neurotoxicity and Abused DrugsHoward E. Gendelman, Andrea Martinez-Skinner, Ari Nowacek, and JoEllyn McMillan: 4.1. Mononuclear phagocyte inflammation and neurotoxicityRuth Brack-Werner, Manja Meggendorfer, Ina Rothenaigner, Bianca Tigges, and Michelle Vincendea: 4.2. Neurotoxicity of HIV-1 proteinsAvindra Nath, Wenxue Li, Guanhan Li, and Joseph Steiner: 4.3. HIV-1 and TatStuart A. Lipton, Shu-ichi Okamoto, Marcus Kaul, Ian Paul Everall, and Eliezer Masliah: 4.4. HIV-1 gp120Guy A. Cabral and Erinn S. Raborn: 4.5. HIV-1 and cannabinoidsHoward S. Fox: 4.6. HIV-1 and METHToby K. Eisenstein, Jessica Breslow, Changcheng Song, Mathew J. Finley, William D. Cornwell, Sumedha Chugh, Joseph J. Meissler, and Thomas J. Rogers: 4.7. HIV-1 and OpioidsShilpa J. Buch, Honghong Yao, and Sabita Roy: 4.8. HIV-1 and Cocaine5. Animal modelsJanice E. Clements, M. Christine Zink, Joseph L. Mankowski, David R. Graham, and Lucio Gama: 5.1. SIVRick B. Meeker: 5.2. FIVValgerdur Andresdottir, Sigurbjorg Torsteinsdottir, and Gudmundur Georgsson: 5.3. CAEVSulie L. Chang and Marley D. Kass: 5.4. TransgenicsLarisa Poluektova: 5.5. Immunodeficient miceShilpa J. Buch, Shannon Callen, Paul Cheney, and Anil Kumar: 5.6. SIV and opiatesJoseph L. Mankowski, Victoria A. Laast, Gigi Ebenezer, and Justin C. McArthur: 5.7. SIV and FIV and peripheral neuropathyR. Gilberto Gonzalez, Eva-Maria Ratai, and Margaret R. Lentz: 5.8. Animal models and bioimaging6. Personal Perspectives in Living with HIV/AIDS6.1. Darren Kane6.2. Eric Glare6.3. James May6.4. Karen6.5. Susan Paxton7. Clinical and Pathologic Manifestations of DiseaseRichard W. Price: 7.1. Prospective on HIV CNS InfectionsIgor Grant and Ned Sacktor: 7.2. HANDSerena S. Spudich: 7.3. Early Manifestations of CNS DiseaseBenjamin B. Gelman and David J. Moore: 7.4. HIV-1 NeuropathologyDavid M. Simpson, Kathryn J. Elliott, and Justin McArthur: 7.5. Peripheral NeuropathyChristina M. Marra: 7.6. Spinal Cord DiseaseSusan Morgello, Jessica Robinson-Papp, Kenneth A. Fox, and David M. Simpson: 7.7. MyopathyChristian L. Achim and Virawudh Soontornniyomkij: 7.8. AgingR. Douglas Bruce: 7.9. Addiction8. Pathogenesis of Co-Morbid ConditionsDennis L. Kolson, Denise R. Cooka, Stephanie A. Crossa, and Samantha S. Soldana: 8.1. NeuroAIDS as an Inflammatory DisorderDianne Langford, Eliezer Masliah, and Ian Paul Everall: 8.2. Neuronal Injury, White Matter Disease, and Neurotrophic FactorsBJ Brew and NWS Davies: 8.3. Pathobiology of HIV-related neuropathiesGeorgette D. Kanmogne and David B. Clifford: 8.4. CNS Co-morbiditiesJoseph R. Berger and Bruce A. Cohen: 8.5. Opportunistic InfectionsEugene O. Major and Maria Chiara G. Monaco: 8.6. PMLAlexis Demopoulos and Lauren Abrey: 8.7. NeoplasmsWenzhe Ho and Li Ye: 8.8. Hepatitis CIan Paul Everall and Timothy B. Nguyen: 8.9. Psychiatric Co-Morbidities9. Diagnostics and BiomarkersLinda Chang, Ute Feger, and Thomas Ernst, Ph.D.: 9.1. Brain ImagingTerry L. Jernigan, Sarah L. Archibald, and Christine Fennema-Notestine: 9.2. MRISteven Paul Woods, Jordan Elizabeth Cattie, and Igor Grant: 9.3. Psychological EvaluationsScott L. Letendre: 9.4. Viral and Cellular Biomarkers During Antiretroviral TherapyRonald J. Ellis and Davey M. Smith: 9.5. Viral DynamicsAvindra Nath and Wenxue Li: 9.6. Viral CladesPawel Ciborowski, Gwenael Pottiez, and Jayme Wiederin: 9.7. Proteomics and Biomarkers10. Children and AdolescentsMark Mintz, Leroy Sharer, and Lucy Civitello: 10.1. Clinical and Pathological Features of HIV-1 Encephalopathy in Children and AdolescentsAnnelies Van Rie and Anna Dow: 10.2. Infants, Children and Adolescents Nervous System Disease in the era of combination antiretroviral therapyLori Wiener and Claude Mellins: 10.3. Psychosocial Aspects of Neurologic Impairment in Children with AIDSLynnae Schwartz, Leslie K. Serchuck, and Shirley F. Delair: 10.4. Growing up with HIV Disease11. Antiretroviral and Adjunctive TherapiesSusan Swindells and Uriel Sandkovsky: 11.1. Current Concepts in the Treatment of HIV Infection with Focus on Brain DiseaseJ. Allen McCutchan, Scott Letendre, Ronald J. Ellis, Brookie Best, and Edmund Capparelli: 11.2. Pharmacology of Antiretroviral TherapiesDavid B. Clifford: 11.3. Treatment of Opportunistic Infections Associated With Human Immunodeficiency Virus InfectionHoward E. Gendelman, Upal Roy, Shantanu Balkundi, and JoEllyn McMillan: 11.4. Nanoformulated MedicinesMadhavan P.N. Nair and Zainulabedin M. Saiyed: 11.5. Antiretroviral nanotherapiesHarris A. Gelbard and Stuart A. Lipton: 11.6. Adjunctive Medicines12. Psychiatry and PsychobiologyJ. Hampton Atkinson, Nichole A. Duarte, and Glenn Treisman: 12.1. Psychiatric DisordersEileen M. Martin-Thomas, Andy Levine, and Raul Gonzalez: 12.2. Neuropsychiatry of Substance AbuseDavid G. Ostrow: 12.3. Psychobiology of Risk BehaviorThomas D. Marcotte, J. Cobb Scott, Charles H. Hinkin, and Robert K. Heaton: 12.4. Everyday Impact of HIV-Associated Neurocognitive DisordersGlenn J. Treisman and Warren B. Treisman: 12.5. Facing Legal and Ethical Challenges in the Treatment of AIDSKevin R. Robertson, Kevin J. Liner, Michelle Ro, and Robert K. Heaton: 12.6. Neuropsychological TestingCharles Wood, Adelina Holguin, and Damien C. Tully: 12.7. The impact of HIV subtype, cultural, and sociodemographic factors on HIV-1 infection and associated neuropathogenesis in Africa